Investors should consider Hims & Hers Health (HIMS) as a high-growth opportunity following its raised 2026 revenue guidance of up to $3 billion, a target that likely "sandbags" the impact of its upcoming Eucalyptus acquisition. The company is aggressively scaling its international footprint and weight loss category, leveraging strategic partnerships with Eli Lilly (LLY) and Novo Nordisk (NVO) to offer branded GLP-1 medications. A key entry point for new patients is Hims Labs, which uses low-cost diagnostic testing to funnel users into high-margin subscription treatments for testosterone and weight loss. While the stock is prone to high volatility, its current valuation appears attractive relative to a projected 30% growth rate and its expansion into AI-driven diagnostics. Long-term investors should monitor the adoption of next-generation drugs like Retatrutide and the company’s transition toward a data-driven "AI doctor" model.

Hims & Hers Health, Inc. (HIMS)

The discussion centers on the company's updated 2026 financial outlook, its aggressive international expansion, and its strategic pivot toward AI-driven healthcare and weight loss treatments. Despite a 10% drop in stock price following the announcement, the sentiment remains highly bullish, with the speaker characterizing the company as a "sandbagger" (a company that sets easily beatable goals).

• Raised 2026 Outlook: The company raised its 2026 revenue guidance to between $2.8 billion and $3 billion.
  • Notably, this guidance excludes the upcoming Eucalyptus acquisition, which is expected to close within the next two months.
  • The speaker estimates that adding Eucalyptus could push 2026 revenue to approximately $3.125 billion, representing a 32% growth rate.
• International Growth: International revenue is currently scaling at 10x year-over-year, reaching $78 million in Q1. The speaker highlights massive Total Addressable Markets (TAM) in Western Europe (200M people), Japan (100M), and the recent launch in Canada.
• Weight Loss & GLP-1 Momentum: The company is seeing near-record adoption in its weight loss category.
  • Strategic partnerships with Eli Lilly (LLY) and Novo Nordisk (NVO) allow Hims to offer the same branded medications a traditional doctor would prescribe.
  • Future interest is focused on Retatrutide (a "GLP-3" next-gen drug) and peptides.
• AI & Diagnostics: Hims is moving toward a "closed-loop proprietary data flywheel" using data from 2.6 million subscribers.
  • Hims Labs: Offers comprehensive lab testing for $349 (often cheaper than insurance). This acts as a "top of the funnel" to identify patients eligible for testosterone or weight loss treatments.
  • AI Care Agent: The company recently launched its first AI agent to interpret lab results, which the speaker views as a precursor to a "full-fledged AI doctor."

Takeaways

• Valuation Opportunity: The speaker notes a "very cheap" Enterprise Value to Gross Profit (EV/GP) ratio of 0.1, suggesting the market is not pricing in future growth.
• Anticipate Volatility: The stock is described as a "roller coaster" with extreme price movements; investors should be prepared for high beta and short-term "trader" influence.
• Watch the "Sandbagging": The company reaffirmed its 2030 guidance, which the speaker believes is intentionally conservative. If the company maintains a ~30% growth rate, it is likely to far exceed its long-term targets.
• Key Verticals to Monitor: Beyond weight loss, investors should watch for growth in Testosterone and Menopause treatments, as these are high-margin, data-dependent sectors.

Eli Lilly (LLY) & Novo Nordisk (NVO)

• These companies are mentioned as critical strategic partners for Hims & Hers.
• Hims is utilizing their FDA-approved weight loss medications to drive record adoption levels on its platform.

Takeaways

• Ecosystem Play: The success of Hims is currently tethered to the supply and popularity of GLP-1 medications produced by these pharmaceutical giants.
• Future Pipeline: Investors should watch for Hims to adopt next-generation drugs from these partners, specifically Retatrutide from Eli Lilly.

Investment Themes & Sectors

Telehealth & Personalized Medicine

• The sector is shifting from simple video calls to "recommender systems" (similar to Netflix or Amazon) that use AI to suggest specific drug profiles and dosages based on patient data.
• Risk Factor: Regulatory changes are a major hurdle. The speaker notes that while some states (like Utah) are moving toward allowing AI-led prescriptions, the full potential of "AI doctors" depends on evolving healthcare laws.

Disruptive Diagnostics

• Moving lab testing from traditional clinics to direct-to-consumer models. By selling labs "at cost," companies can acquire high-intent customers for long-term subscription treatments (Testosterone, Peptides, etc.).